GU Oncology Now

20/12/2021

Latest from Telix Pharmaceuticals Limited! The had approved the company’s lead imaging asset called Illuccix
Read about it here:

Telix Pharmaceuticals today announces that the US Food and Drug Administration (FDA) has approved the company's lead prostate cancer imaging asset, called

20/12/2021

Dr. Neeraj Agarwal discusses PSMA Imaging with Dr. Jonathan Tward, Dr. Scott Tagawa, and Dr. Jeremie Calais

In the first video of the roundtable series, Dr. Jeremie Calais reviews the basics of PSMA as a biological target for the PET imaging of prostate cancer.

25/11/2021

On this Thanksgiving, we want to share our genuine appreciation for you. We wouldn’t be where we are today without you!

16/11/2021

PSMA (prostate-specific membrane antigen) is over-expressed on the membrane of aggressive prostate cancer (PCa) cells, and as such has been found to be a promising target for the treatment of advanced PCa.

09/11/2021

Prognostic value of lower urinary tract symptoms (LUTS) in with newly diagnosed regional lymph node-positive

A study explored the prognostic value of lower urinary tract symptoms (LUTS) in patients with newly diagnosed regional lymph node-positive prostate

08/11/2021

Latest podcast from the ! Interview with Dr. Sam Gledhill

Sam Gledhill describes Movember and its work.   Tom: We're joined here today by Sam Gledhill from Movember. He's the... For digital health for the

08/11/2021

PSMA-PET findings support risk groups based on the Prostate Cancer Guidelines Panel for biochemically recurrent (BCR)

Prostate-specific membrane antigen (PSMA)-positron emission tomography (PET) findings support risk groups based on the European Association of Urology

02/11/2021

Physicians use precision medicine to discern people who might be at risk for cancer, identify cancer in its early stages, prevent some forms of cancer, choose the best treatment option.

Read more: https://www.docwirenews.com/gu-oncology-now/phenotypic-precision-medicine-gu-kh/the-benefits-of-precision-medicine-in-cancer/?utm_source=social&utm_medium=social&utm_campaign=social&utm_content=social

Precision medicine, often referred to as personalized medicine, is a form of medicine that utilizes information about an individual’s genes or proteins to

26/10/2021

discussed novel therapies that are shaping the way advanced prostate cancer is treated.

Read more: https://www.docwirenews.com/condition-center/precision-medicine-in-prostate-cancer/precision-medicine-in-prostate-cancer-picks/dr-dan-george-duke-health-on-phenotypic-precision-medicine-in-prostate-cancer/?utm_source=social&utm_medium=social&utm_campaign=social&utm_content=social

GU Oncology Now recently spoke with Daniel Geroge, MD, a medical oncologist at Duke Cancer Center who specializes in genitourinary cancers. Dr. George

25/10/2021

A preliminary study from assessed the link of circulating tumor cells (CTC) with inflammatory biomarkers in patients with metastatic castration-resistant prostate cancer (mCPRC).

Read more: https://www.docwirenews.com/gu-oncology-now/gu-oncology-now-picks/study-explores-link-between-ctc-count-and-inflammation-in-advanced-prostate-cancer/?utm_source=social&utm_medium=social&utm_campaign=social&utm_content=social

A preliminary study assessed the link of circulating tumor cells (CTC) with inflammatory biomarkers in patients with metastatic castration-resistant

24/10/2021

Throw back! and discuss the accelerated approval.
https://www.docwirenews.com/gu-oncology-now/the-uromigos/uromigos-a-podcast/episode-96-odac-bladder-cancer-accelerated-approval-meeting/?utm_source=social&utm_medium=Social&utm_campaign=Social&utm_content=Social

Andrea Apollo discusses highlights from the April 28th meeting.

23/10/2021

NEW INTERVIEW! of discusses the development of new approaches to treating advanced
https://www.docwirenews.com/gu-oncology-now/phenotypic-precision-medicine-gu-kh/dr-andrew-armstrong-on-precision-medicine-approaches-in-advanced-prostate-cancer/?utm_source=social&utm_medium=Social&utm_campaign=Social&utm_content=Social

GU Oncology Now recently spoke with Andrew J. Armstrong, MD, a physician at Duke Cancer Institute Center for Prostate and Urologic Cancers. Dr. Armstrong